INHALATION SCIENCES SWEDEN AB
NNGM:ISAB0.06
SEK
+0.00
(+0.33%)
INHALATION SCIENCES SWEDEN AB
NGM:ISAB
(Nordic Growth Market)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Inhalation Sciences Sweden AB is a medical technology and contract research organization that develops, manufactures, and commercializes precision laboratory instruments and analytical testing services for inhalation drug development and respiratory research. Founded in 2004 and headquartered in Huddinge, Sweden, the company provides preclinical tools designed to characterize aerosol behavior, optimize drug delivery, and de-risk pharmaceutical formulations for global pharmaceutical corporations, biotechnology enterprises, contract research organizations, and academic institutions across Europe, North America, and the Asia-Pacific region. The company's core commercial offerings are structured around its proprietary instrumentation platforms and contract research services: the PreciseInhale platform, an aerosol generation and exposure system delivering controlled micro-dosing of dry powders, nebulized liquids, pressurized metered-dose inhalers (pMDIs), and dry powder inhalers (DPIs) with low substance consumption; DissolvIt, an in vitro dissolution testing module that simulates physiological lung conditions to measure active substance dissolution and absorption kinetics; XposeALI, an in vitro 3D cell exposure module that tests aerosol deposition on lung cell cultures at the air-liquid interface; Nose-Only Inhalation, an in vivo exposure module providing active dosing control for rodent studies; Intratracheal Inhalation, an in vivo module delivering aerosols directly into the lungs of spontaneously breathing rodents; and Inhalation Research Services (IRS), a contract research division offering customized pharmacokinetic profiling, aerosol characterization, in vitro dissolution testing, and early-stage formulation screening. In recent developments, Inhalation Sciences Sweden AB has advanced several strategic, commercial, and operational initiatives. The company engaged transaction advisory firm PharmaVentures Ltd. to explore strategic alternatives, including potential corporate partnerships and commercial transaction options. Scientifically, the company advanced the commercial validation of its DissolvIt platform through a research collaboration study funded by the U.S. Food and Drug Administration (FDA) and secured participation and grant funding in the European BioInhale research consortium for Isolated Perfused Lung studies. Organizationally, the company announced the appointment of Pontus Nobréus as Chief Executive Officer to lead commercial expansion and operational restructuring. To support ongoing operations and working capital, the company strengthened its liquidity position through the execution of working capital loan facilities with Nordic investment groups and the utilization of its series TO3 subscription warrants.